TA103

Sun Pharmaceutical Industries, Inc. · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	TA103
Also known as	Test Product
Sponsor	Sun Pharmaceutical Industries, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis. (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TA103 CI brief — competitive landscape report
TA103 updates RSS · CI watch RSS
Sun Pharmaceutical Industries, Inc. portfolio CI